Intrinsic and acquired resistance to cetuximab in colorectal cancer patients

被引：0
|
作者：
Bray, Steven M.
Lee, Jeeyun
Kim, Seung Tae
Ebert, Philip J.
Calley, John N.
Wulur, Isabella H.
Gopalappa, Thejaswini
Wong, Swee Seong
Qian, Hui-Rong
Ting, Jason C.
Liu, Jiangang
Willard, Melinda D.
Aggarwal, Amit
Novosiadly, Ruslan D.
Kim, Hee-Cheol
Reinhard, Christoph
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4104
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
    Tak, Eunyoung
    Kim, Minhee
    Cho, Youngra
    Choi, Sueun
    Kim, Jihun
    Han, Buhm
    Kim, Hyung-Don
    Jang, Chloe Soo-Hyun
    Kim, Jeong Eun
    Hong, Yong Sang
    Kim, Sun Young
    Kim, Tae Won
    ONCOLOGY REPORTS, 2022, 47 (01)
  • [22] Cetuximab Sensitivity Associated with Oxaliplatin Resistance in Colorectal Cancer
    Ekblad, Lars
    Johnsson, Anders
    ANTICANCER RESEARCH, 2012, 32 (03) : 783 - 786
  • [23] Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
    Bardelli, Alberto
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1254 - 1261
  • [24] Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? (vol 23, pg 2313, 2012)
    Santini, D.
    Vincenzi, B.
    Addeo, R.
    Garufi, C.
    Masi, G.
    Scartozzi, M.
    Mancuso, A.
    Frezza, A. M.
    Venditti, O.
    Imperatori, M.
    Schiavon, G.
    Bronte, G.
    Cicero, G.
    Recine, F.
    Maiello, E.
    Cascinu, S.
    Russo, A.
    Falcone, A.
    Tonini, G.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2906 - 2906
  • [25] Mechanism of acquired resistance to cetuximab in head and neck cancer.
    Khattri, Arun
    Sheikh, Nizamuddin
    Acharya, Rajesh
    Tan, Yi-Hung Carol
    Kochanny, Sara
    Lingen, Mark W.
    Vokes, Everett E.
    Seiwert, Tanguy Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer
    Ye, Song
    Hu, Xiaoge
    Ni, Chao
    Jin, Weiwei
    Xu, Yaping
    Chang, Lianpeng
    Zhou, Huaixiang
    Jiang, Jiahong
    Yang, Liu
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (03) : 956 - 965
  • [27] The anti-EGFR antibody mixture Sym004 overcomes acquired resistance to cetuximab in colorectal cancer
    Sanchez-Martin, Francisco J.
    Dalmases, Alba
    Bellosillo, Beatriz
    Argiles, Guillem
    Gelabert, Mariona
    Canadas, Israel
    Vidal, Joana
    Siravegna, Giulia
    Arena, Sabrina
    Koefoed, Klaus
    Visa, Laura
    Arpf, Oriol
    Horak, Ivan D.
    Iglesias, Mar
    Stroh, Christopher
    Kragh, Michael
    Rovira, Ana
    Albanell, Joan
    Bardelli, Alberto
    Tabernero, Josep
    Montagut, Clara
    CANCER RESEARCH, 2016, 76
  • [28] Effect of Sym004 on acquired resistance to cetuximab in colorectal cancer (CRC) in a novel mouse avatar model
    Vangala, Deepak B.
    Liffers, Sven T.
    Pohl, Michael
    Teschendorf, Christian
    Tannapfel, Andrea
    Schmiegel, Wolff H.
    Hahn, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Cetuximab improves survival in patients with colorectal cancer
    Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5 (3): : 122 - 122
  • [30] Cetuximab rechallenge in metastatic colorectal cancer patients
    Nogueira, A.
    Rodrigues, J.
    Jacinto, P.
    Ribeiro, J.
    Bonito, N.
    Marques, M.
    Gervasio, H.
    ANNALS OF ONCOLOGY, 2016, 27 : 49 - 50
12345